About Exosiris
Exosiris is pioneering nanomedicine for targeted therapeutic delivery, enabling innovative treatments in oncology, for regenerative medicine and autoimmune diseases, making advanced therapies accessible worldwide.
Democratization of therapies for unmet clinical needs, transforming healthcare together
Leadership Team
Maria Loustau, Ph.D. – CSO
Biotech leader with nearly 20 years of experience in immunotherapy R&D and management. Developer of first-in-class anti-HLA-G CAR-T cells and pioneer in antibodies, nanobodies, and checkpoint targets. Co-inventor on 7 patents, recipient of CPRIT funding, and recognized twice by MATWIN for innovation.
Leadership
Julien Caumartin, Ph.D. – CEO
Immunologist with 15+ years of expertise in tumor immune evasion and CAR-T engineering. Co-developed the first anti-HLA-G CAR-T cells (now in clinical trials at MD Anderson) and advanced novel CAR strategies against “undruggable” tumor antigens. Recognized leader in bridging fundamental immunology with translational innovation.
Scientific Co-Founders & Advisors
Recreate the future
Dr. XX
Dr. XX
Dr. XX
Dr. XX